Inflammation predicts CV events ‘better than lipids’ in patients taking statins
Combined use of aggressive lipid-lowering and anti-inflammatory therapies might become the new 'standard of care for atherosclerotic disease', say researchers.
Vascular inflammation is a better predictor of future cardiovascular events and death than LDL cholesterol in patients on statin therapy, US doctors report.
Their meta-analysis of three large clinical trials also suggests the risk of adverse outcomes is higher in those with high-sensitivity CRP ≥2mg/L regardless of atherogenic lipid levels.
